Login / Register

CME Event Calendar

CME Online Activities

Other Activities

CME Peer-to-Peer Dialogue

ITPeducation.com™ CME Peer-to-Peer Dialogue features insightful audio commentary from a multidisciplinary group of experts in hematology and oncology. Listen in for state-of-the-art information as they address timely, clinically relevant topics identified by the ITPeducation.com^™ faculty.

ITP CME Peer-to-Peer Dialogue

Subscribe to Podcast

Download iTunes®

RSS Feed

 

	What are the clinical findings that lead to a diagnosis of ITP? What pathologic mechanisms underlie the disease? How is the adult disease different from ITP in children? Click here for Credit CME Activity Expires: July 31, 2010
	What are the major approaches? How is success defined and what is the evidence for each approach? What are the thrombopoietic agents that were recently approved, and what should practitioners know about their efficacy and safety? Are there emerging approaches that offer other therapeutic avenues? Click here for Credit CME Activity Expires: August 31, 2010
	What are the major QoL indicators for patients with ITP? Is there a validated QoL instrument for ITP and how should it be used in clinical practice? What is the clinical evidence that immunosuppressive and thrombopoietic therapies improve these indicators? What is the clinical evidence that splenectomy improves these indicators? Click here for Credit CME Activity Expires: September 30, 2010
	What is the most critical information regarding efficacy and safety to share with patients during each phase of ITP management? What are the risk/benefit considerations of the new thrombopoietic agents? What are the positive and negative outcome predictors for splenectomy? Are there biomarkers that can help select the best patients for different therapies or predict outcomes?   Click here for Credit CME Activity Expires: October 31, 2010
	What is the liver's role in platelet homeostasis and how is it affected by chronic liver disease? Are there special considerations for different types of chronic liver disease? What is the role of anti-platelet antibodies in thrombocytopenia associated with CLD? What is the evidence on the use of thrombopoietic agents in this patient population? Click here for Credit CME Activity Expires: November 30, 2010.
	What is the pathologic connection between thrombocytopenia and cancer? What is the evidence on the use of thrombopoietic agents in patients with cancer and thrombocytopenia? Does the danger of thromboembolism in patients with cancer influence the management of thrombocytopenia?   Click here for Credit CME Activity Expires: November 30, 2010.
Management of ITP
	What is the role of splenectomy in managing ITP? How efficacious is the procedure, which patients should receive this treatment, and what are the safety concerns? CME Activity Expired: October 31, 2009. CME credit no longer available.
	What medications are currently available to treat ITP and which are in clinical evaluation? How efficacious are they and for which patients are they most appropriate? What are the safety concerns with each?   CME Activity Expired: November 30, 2009. CME credit no longer available.
	What is the optimal strategy for monitoring ITP patients? Describe any patient assessment and educational tools (or resources) that can help track therapeutic progress and can help to improve compliance in patients with ITP. CME Activity Expired: December 31, 2009. CME credit no longer available.
Diagnosis of ITP
	What are the critical pathophysiological processes underlying ITP?   CME Activity Expired: July 31, 2009. CME credit no longer available.
	Accurate recognition of ITP involves excluding other conditions and causes of thrombocytopenia. What are the most common causes of thrombocytopenia that must be considered? CME Activity Expired: August 31, 2009. CME credit no longer available.
	What are the critical pathophysiological processes underlying ITP?   CME Activity Expired: September 30, 2009. CME credit no longer available.